Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    "Toxic epidermal necrolysis"
Show Display Options
Rank Status Study
1 Completed Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Conditions: Stevens-Johnson Syndrome;   Toxic Epidermal Necrolysis
Intervention: Drug: Intravenous immunoglobulin
2 Recruiting Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
Conditions: Toxic Epidermal Necrolysis;   Stevens-Johnson Syndrome
Intervention: Drug: Palifermin
3 Withdrawn Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
Condition: Toxic Epidermal Necrolysis
Intervention: Drug: Remicaide (infliximab)
4 Enrolling by invitation Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
Conditions: Stevens-Johnson Syndrome;   Toxic Epidermal Necrolysis (Lyell) Syndrome;   Mucous Membrane Pemphigoid
Intervention: Drug: topical infliximab
5 Recruiting Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
Conditions: Stevens-Johnson Syndrome;   Corneal Blindness
Intervention: Drug: Infliximab

Indicates status has not been verified in more than two years